Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.

Also called NCT02150824

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 103 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02150824
  • EudraCT 2013-003646-16
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02150824. Randomized; double masking; primary purpose treatment. Start 2014-07 (registry gives no type); primary completion 2015-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
BI 187004
Intervention (Drug)
Placebo
Intervention (Drug)
BI 187004
Intervention (Drug)
BI 187004
Intervention (Drug)
BI 187004
Lead sponsor
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct02150824
Content hash
0f551e1e4168cd62a4c4e58c99b0522c1f9d8611cb17c60b556ad8ae81aeebc6